Results 11 to 20 of about 2,047,581 (349)

Systemic analysis of the AST results in medical organizations of the Russian Feder ation [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
Objective. To analyse aggregated AST results for key microorganisms collected through the 2022 reports of chief specialists in clinical microbiology and antimicrobial resistance. Materials and Methods.
Vinogradova A.G., Kuzmenkov A.Yu., Trushin I.V., Sukhorukova M.V., Kozlov R.S.   +4 more
doaj   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

New England Journal of Medicine, 2022
BACKGROUND In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed ...
J. Cortés, H. Rugo, D. Cescon, S. Im, M. Yusof, C. Gallardo, O. Lipatov, C. Barrios, J. Peréz-García, H. Iwata, N. Masuda, M. Torregroza Otero, E. Gokmen, S. Loi, Zifang Guo, Xuan Zhou, V. Karantza, W. Pan, P. Schmid   +18 more
semanticscholar   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

New England Journal of Medicine, 2023
BACKGROUND Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear.
R. Eskander, M. Sill, L. Beffa, Richard G. Moore, J. Hope, Fernanda B. Musa, R. Mannel, M. Shahin, G. Cantuaria, E. Girda, C. Mathews, J. Kavecansky, Charles A Leath Iii, L. Gien, E. Hinchcliff, S. Lele, L. Landrum, F. Backes, R. O'Cearbhaill, T. Al baghdadi, E. Hill, P. Thaker, V. John, S. Welch, A. Fader, M. Powell, C. Aghajanian   +26 more
semanticscholar   +1 more source

Antimicrobial resistance of clinical isolates of Klebsiella pneumoniae and Escherichia coli in Russian hospitals: results of a multicenter epidemiological study [PDF]

Клиническая микробиология и антимикробная химиотерапия
Objective. To study the prevalence and mechanisms of antibiotic resistance, including carbapenemase production, in clinical isolates of Klebsiella pneumoniae and Escherichia coli isolated in different regions of Russia as part of the sentinel ...
Edelstein M.V., Shajdullina E.R., Ivanchik N.V., Dekhnich A.V., Mikotina A.V., Skleenova E.Yu., Sukhorukova M.V., Azyzov I.S., Shek E.A., Romanov A.V., Trushin I.S., Kuzmenkov A.Yu., Kozlov R.S.   +12 more
doaj   +1 more source

Severe anaphylaxis caused by intravenous anti‐cancer drugs

Cancer Medicine, 2021
Background The incidence and risk factors of severe anaphylaxis by intravenous anti‐cancer drugs are unclear, whereas those of milder reactions have been reported.
Nobuyuki Horita, Etsuko Miyagi, Taichi Mizushima, Maki Hagihara, Chiaki Hata, Yuki Hattori, Narihiko Hayashi, Kuniyasu Irie, Hideyuki Ishikawa, Yusuke Kawabata, Yosuke Kitani, Noritoshi Kobayashi, Nobuaki Kobayashi, Yusuke Kurita, Yohei Miyake, Kentaro Miyake, Senri Oguri, Ichiro Ota, Ayako Shimizu, Masanobu Takeuchi, Akimitsu Yamada, Kojiro Yamamoto, Norio Yukawa, Munetaka Masuda, Nobuhiko Oridate, Yasushi Ichikawa, Takeshi Kaneko   +26 more
doaj   +1 more source

Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

New England Journal of Medicine, 2018
BACKGROUND First‐line therapy for advanced non–small‐cell lung cancer (NSCLC) that lacks targetable mutations is platinum‐based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD‐L1) of 50% or greater ...
L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Dómine, P. Clingan, M. Hochmair, S. Powell, S. Cheng, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J. Gray, J. Vida, Ziwen Wei, Jing Yang, H. Raftopoulos, C. Pietanza, M. Garassino   +28 more
semanticscholar   +1 more source

First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer

New England Journal of Medicine, 2018
BACKGROUND Enhancing tumor‐specific T‐cell immunity by inhibiting programmed death ligand 1 (PD‐L1)–programmed death 1 (PD‐1) signaling has shown promise in the treatment of extensive‐stage small‐cell lung cancer.
L. Horn, A. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M. Hochmair, F. Huemer, G. Losonczy, M. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D. Shames, Juan Liu, B. Ding, A. López-Chávez, F. Kabbinavar, W. Lin, A. Sandler, Stephen V. Liu   +20 more
semanticscholar   +1 more source

Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer

New England Journal of Medicine, 2018
Background Standard first‐line therapy for metastatic, squamous non–small‐cell lung cancer (NSCLC) is platinum‐based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD‐L1] expression on ≥50% of tumor cells).
L. Paz-Ares, A. Luft, D. Vicente, A. Tafreshi, M. Gümüş, J. Mazières, B. Hermes, F. Senler, T. Csőszi, A. Fülöp, J. Rodríguez-Cid, Jonathan Wilson, S. Sugawara, T. Kato, K. Lee, Ying Cheng, S. Novello, B. Halmos, Xiaodong Li, G. Lubiniecki, B. Piperdi, D. Kowalski   +21 more
semanticscholar   +1 more source

Myoferlin disturbs redox equilibrium to accelerate gastric cancer migration

Frontiers in Oncology, 2022
ObjectiveIn contrast to normal cells, in which reactive oxygen species (ROS) are maintained in redox equilibrium, cancer cells are characterized by ectopic ROS accumulation.
Hailong Shi, Yuanyuan Cheng, Qimei Shi, Wenzhi Liu, Xue Yang, Shuang Wang, Lin Wei, Xiangming Chen, Hao Fang   +8 more
doaj   +1 more source

Antiviral chemotherapy [PDF]

Infection, 1984
After a discussion of the principles of antiviral chemotherapy, treatment and chemoprophylaxis of the following virus infections are reviewed in detail: the various manifestations of herpes simplex virus infections, varicella-zoster, cytomegalovirus infections, Epstein-Barr virus infections, laryngeal papillomas, and influenza A.
openaire   +3 more sources